|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics development for multiple disease indications. |
|
| Management |
| Dr. Tony Cruz, Chief Executive Officer; Elie Farah, President & Chief Financial Officer; Dr. Aleksandra Pastrak, VP of Research and Medical Officer; Mr. Carl Damiani, VP Business Development; Ms. Laura Agensky, VP Clinical Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| gastrin, insulin-producing, islet beta, hyperglycemia, diabetes |
|
|
|
| Description |
|
Transition Therapeutics Inc. is focused on a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. |
|
| Products / Services |
Transition's Islet Neogenesis Therapy (I.N.T.) offers a new hope and a chance to live a "normal" life for millions of diabetic patients who are dependent on daily insulin injections and strict diet regimens. This breakthrough technology has the potential to reduce or eliminate the need for regular insulin injections for months or even years by regenerating the body's own insulin-producing cells with a short-course treatment.
|
|
| Technology / Differentiation |
| Transition's gastrin-based therapies offer a new hope and a chance to live a "normal" life for millions of diabetes patients who are dependent on daily insulin injections and strict diet regimens. They have the potential to reduce or eliminate the need for regular insulin injections for months or even years by regenerating the body's own insulin-producing cells with a short-course treatment. The potential market size in the U.S. alone is estimated to be over US$16 billion. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
